

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \*    Welcome to STN International    \* \* \* \* \* \* \* \* \*

NEWS 1                Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2                "Ask CAS" for self-help around the clock  
NEWS 3 JAN 17        Pre-1988 INPI data added to MARPAT  
NEWS 4 FEB 21        STN AnaVist, Version 1.1, lets you share your STN AnaVist  
                      visualization results  
NEWS 5 FEB 22        The IPC thesaurus added to additional patent databases on STN  
NEWS 6 FEB 22        Updates in EPFULL; IPC 8 enhancements added  
NEWS 7 FEB 27        New STN AnaVist pricing effective March 1, 2006  
NEWS 8 MAR 03        Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 9 MAR 22        EMBASE is now updated on a daily basis  
NEWS 10 APR 03       New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 11 APR 03       Bibliographic data updates resume; new IPC 8 fields and IPC  
                      thesaurus added in PCTFULL  
NEWS 12 APR 04       STN AnaVist \$500 visualization usage credit offered  
NEWS 13 APR 12       LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 14 APR 12       Improved structure highlighting in FQHIT and QHIT display  
                      in MARPAT  
NEWS 15 APR 12       Derwent World Patents Index to be reloaded and enhanced during  
                      second quarter; strategies may be affected  
NEWS 16 MAY 10       CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEWS 17 MAY 11       KOREPAT updates resume  
NEWS 18 MAY 19       Derwent World Patents Index to be reloaded and enhanced  
  
NEWS EXPRESS        FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
                      CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
                      AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
                      V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
                      <http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS         STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN         Welcome Banner and News Items  
NEWS IPC8         For general information regarding STN implementation of IPC 8  
NEWS X25         X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \*

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 13:43:37 ON 30 MAY 2006

=> file caplus  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 13:43:46 ON 30 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 May 2006 VOL 144 ISS 23  
FILE LAST UPDATED: 29 May 2006 (20060529/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s (huntingtin interacting) or HIP1
    1115 HUNTINGTIN
        83 HUNTINGTINS
    1131 HUNTINGTIN
        (HUNTINGTIN OR HUNTINGTINS)
80906 INTERACTING
    133 HUNTINGTIN INTERACTING
        (HUNTINGTIN(W) INTERACTING)
    136 HIP1
        217 (HUNTINGTIN INTERACTING) OR HIP1
```

=> s antibod?

=> s autoantibod?  
L3 18650 AUTOANTIBOD?

=> s 12 or 13  
L4 464482 L2 OR L3

=> s serum or sera or blood or urine

549523 SERUM  
16762 SERUMS  
46396 SERA  
9 SERAS  
573992 SERUM  
(SERUM OR SERUMS OR SERA OR SERAS)  
46396 SERA  
9 SERAS  
46402 SERA  
(SERA OR SERAS)  
1243345 BLOOD  
1218 BLOODS  
1243478 BLOOD  
(BLOOD OR BLOODS)  
210455 URINE  
4453 URINES  
210883 URINE  
(URINE OR URINES)

L5 1605105 SERUM OR SERA OR BLOOD OR URINE

=> s 15 (S) 14  
L6 75911 L5 (S) L4

=> s 14 (S) 15  
L7 75911 L4 (S) L5

=> s 14 (2W) 15  
L8 13791 L4 (2W) L5

=> s 18 and 11  
L9 0 L8 AND L1

=> s 15 (2W)  
MISSING TERM AFTER L5 (2W)  
Operators must be followed by a search term, L-number, or query name.

=> s 16 and 14  
L10 75911 L6 AND L4

=> s 16 and 11  
L11 5 L6 AND L1

=> d ibib 1-5

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:104603 CAPLUS  
DOCUMENT NUMBER: 144:169114  
TITLE: Analysis of gene expression profiles in urine and blood in early diagnosis of bladder cancer  
INVENTOR(S): Guilford, Parry, John; Kerr, Natalie, Jane; Pollock, Robert  
PATENT ASSIGNEE(S): Pacific Edge Biotechnology Ltd., N. Z.; Farmer, Charles, Davis, Jr.  
SOURCE: PCT Int. Appl., 123 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012522	A1	20060202	WO 2005-US26055	20050722
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: NZ 2004-534289 A 20040723  
NZ 2005-539219 A 20050404  
US 2005-692619P P 20050620

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:430537 CAPLUS

DOCUMENT NUMBER: 143:94728

TITLE: Serum antibodies to

Huntingtin interacting protein-1: A new blood test for prostate cancer

AUTHOR(S): Bradley, Sarah V.; Oravec-Wilson, Katherine I.; Bougeard, Gaelle; Mizukami, Ikuko; Li, Lina; Munaco, Anthony J.; Sreekumar, Arun; Corradetti, Michael N.; Chinnaiyan, Arul M.; Sanda, Martin G.; Ross, Theodora S.

CORPORATE SOURCE: Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

SOURCE: Cancer Research (2005), 65(10), 4126-4133

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:417568 CAPLUS

DOCUMENT NUMBER: 139:5159

TITLE: Overexpressed in cancer of huntingtin

interacting protein, HIP1,

antibodies, HIP1-encoding nucleic acids, and

diagnostic and therapeutic uses

INVENTOR(S): Ross, Theodora; Mizukami, Ikuko; Roa, Dinesh

PATENT ASSIGNEE(S): The Regents of the University of Michigan, USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043566	A2	20030530	WO 2002-US36175	20021112
WO 2003043566	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2003124533 A1 20030703 US 2001-7047 20011206  
 CA 2467459 AA 20030530 CA 2002-2467459 20021112  
 AU 2002359381 A1 20030610 AU 2002-359381 20021112  
 EP 1527190 A2 20050504 EP 2002-793914 20021112  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
 US 2004265929 A1 20041230 US 2004-767325 20040129  
 WO 2005072457 A2 20050811 WO 2005-US3330 20050128  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG  
 PRIORITY APPLN. INFO.: US 2001-335276P P 20011115  
 US 2001-7047 A 20011206  
 WO 2002-US36175 W 20021112  
 US 2004-767325 A 20040129

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1993:557906 CAPLUS  
 DOCUMENT NUMBER: 119:157906  
 TITLE: The comparative study on binding sites of McAb-HIP1, HIP2, HIP7, APT4; and Sj-9A4 on platelet surface membrane  
 AUTHOR(S): Liu, Jiewen; Wang, Meijian; et al.  
 CORPORATE SOURCE: Inst. Hematol., CAMS, Tianjin, 300020, Peop. Rep. China  
 SOURCE: Zhonghua Xueyexue Zazhi (1993), 14(3), 118-20  
 DOCUMENT TYPE: CODEN: CHTCD7; ISSN: 0253-2727  
 LANGUAGE: Journal  
 Chinese  
  
 L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1991:511356 CAPLUS  
 DOCUMENT NUMBER: 115:111356  
 TITLE: Changes of cytosolic calcium concentration in fura-2-loaded human platelets induced by monoclonal antibodies HIP2, APT4, HI117 and SJ-9A4  
 AUTHOR(S): Wang, Meijian; Yu, Aixin; Li, Jiazeng  
 CORPORATE SOURCE: Inst. Hematol., Chin. Acad. Med. Sci., Tianjin, Peop. Rep. China  
 SOURCE: Zhonghua Xueyexue Zazhi (1991), 12(2), 58-60, 110  
 DOCUMENT TYPE: CODEN: CHTCD7; ISSN: 0253-2727  
 LANGUAGE: Journal  
 Chinese

=> file pctfull	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	26.93	27.14

FILE LAST UPDATED: 23 MAY 2006 <20060523/UP>  
MOST RECENT UPDATE WEEK: 200620 <200620/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.

SEE

[>>>](http://www.stn-international.de/stndatabases/details/ipc-reform.html)

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE  
(last updated April 10, 2006) <<<

=> s (huntingtin interacting) or HIP1

490 HUNTINGTIN  
6 HUNTINGTINS  
491 HUNTINGTIN  
(HUNTINGTIN OR HUNTINGTINS)

38966 INTERACTING  
132 HUNTINGTIN INTERACTING  
(HUNTINGTIN (W) INTERACTING)

37 HIP1  
L12 152 (HUNTINGTIN INTERACTING) OR HIP1

=> s antibod?

L13 88064 ANTIBOD?

=> s autoantibod?

L14 2913 AUTOANTIBOD?

=> s l14 or l13

L15 88157 L14 OR L13

=> s serum or sera or blood or urine

88399 SERUM  
1418 SERUMS  
48167 SERA  
120467 SERUM  
(SERUM OR SERUMS OR SERA)  
48167 SERA  
45 SERAS  
48182 SERA  
(SERA OR SERAS)

131048 BLOOD  
285 BLOODS  
131061 BLOOD  
(BLOOD OR BLOODS)  
26898 URINE  
426 URINES  
27016 URINE  
(URINE OR URINES)

L16 190292 SERUM OR SERA OR BLOOD OR URINE

=> s l15 (S) l16

L17 43564 L15 (S) L16

=> s l16 (4W) l16

L18 49900 L16 (4W) L16

=> s l16 (4W) l15

L19 10830 L16 (4W) L15

=> s l19 and l12

L20

13 L19 AND L12

=> s 120 not py>2002  
401094 PY>2002  
L21 8 L20 NOT PY>2002

=> d ibib 1-4

L21 ANSWER 1 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2002094864 PCTFULL ED 20021210 EW 200248  
TITLE (ENGLISH): HUMAN CDNAS AND PROTEINS AND USES THEREOF  
TITLE (FRENCH): ADNC ET PROTEINES HUMAINES, AINSI QUE LEURS  
UTILISATIONS  
INVENTOR(S): BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009  
Paris, FR [FR, FR];  
TANAKA, Hiroaki, 8, avenue de la Providence, F-92160  
Antony, FR [FR, FR]  
PATENT ASSIGNEE(S): GENSET, Intellectual Property Department, 24, rue  
Royale, F-75008 Paris, FR [FR, FR], for all designates  
States except US;  
BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009  
Paris, FR [FR, FR], for US only;  
TANAKA, Hiroaki, 8, avenue de la Providence, F-92160  
Antony, FR [FR, FR], for US only  
AGENT: GENSET\$, Intellectual Property Department, 24, rue  
Royale, F-75008 Paris\$, FR  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:  
NUMBER KIND DATE  
-----  
WO 2002094864 A2 20021128  
DESIGNATED STATES  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL  
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
RW (ARIPO): AM AZ BY KG KZ MD RU TJ TM  
RW (EAPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR  
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
APPLICATION INFO.: WO 2001-IB1715 A 20010806  
PRIORITY INFO.: US 2001-60/293,574 20010525  
US 2001-60/298,698 20010615  
US 2001-60/302,277 20010629  
US 2001-60/305,456 20010713

L21 ANSWER 2 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2002060934 PCTFULL ED 20020815 EW 200232  
TITLE (ENGLISH): IDENTIFICATION OF THE ANTI-&sigma;<sp>28</sp> FACTOR IN  
HELICOBACTER PYLORI, IN CAMPYLOBACTER JEJUNI AND IN  
PSEUDOMONAS AERUGINOSA AND APPLICATION THEREOF  
TITLE (FRENCH): IDENTIFICATION DU FACTEUR ANTI-\$G(S)<sp>28</sp> CHEZ  
HELICOBACTER PYLORI, CAMPYLOBACTER JEJUNI ET  
PSEUDOMONAS AERUGINOSA ET APPLICATION DE CELUI-CI  
INVENTOR(S): LEGRAIN, Pierre, 5, rue Mizon, F-75015 Paris, FR [FR,  
FR];  
COLLAND, Frederic, 12, avenue de Haute Greve, F-95470  
Fosses, FR [FR, FR];  
RAIN, Jean-Christophe, 32, Jardins Boieldieu, F-92800  
Puteaux, FR [FR, FR];

PATENT ASSIGNEE(S): LABIGNE, Agnes, 47, avenue Beausejour, F-91440  
Bures-sur-Yvette, FR [FR, FR];  
DE REUSE, Hilde, 49, rue Rouelle, F-75015 Paris, FR  
[FR, FR]  
HYBRIGENICS, 3-5 Impasse Reille, F-75014 Paris, FR [FR,  
FR], for all designates States except US;  
INSTITUT PASTEUR, 25-28, rue du Dr. Roux, F-75724 Paris  
Cedex 15, FR [FR, FR], for all designates States except  
US;  
LEGRAIN, Pierre, 5, rue Mizon, F-75015 Paris, FR [FR,  
FR], for US only;  
COLLAND, Frederic, 12, avenue de Haute Greve, F-95470  
Fosses, FR [FR, FR], for US only;  
RAIN, Jean-Christophe, 32, Jardins Boieldieu, F-92800  
Puteaux, FR [FR, FR], for US only;  
LABIGNE, Agnes, 47, avenue Beausejour, F-91440  
Bures-sur-Yvette, FR [FR, FR], for US only;  
DE REUSE, Hilde, 49, rue Rouelle, F-75015 Paris, FR  
[FR, FR], for US only  
DESAIX, Anne\$, Ernest Gutmann-Yves Plasseraud S.A., 3,  
rue Chauveau-Lagarde, F-75008 Paris\$, FR  
English  
English  
Patent

AGENT:

LANGUAGE OF FILING:  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE:  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002060934	A2	20020808

DESIGNATED STATES  
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI  
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW  
GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW  
AM AZ BY KG KZ MD RU TJ TM  
AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR  
BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
RW (ARIPO):  
RW (EAPO):  
RW (EPO):  
RW (OAPI):  
APPLICATION INFO.: WO 2002-EP1625 A 20020128  
PRIORITY INFO.: US 2001-60/265,465 20010131

L21 ANSWER 3 OF 8  
ACCESSION NUMBER: 2002036741  
TITLE (ENGLISH): PCTFULL COPYRIGHT 2006 Univentio on STN  
POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN  
T-LYMPHOCYTE-DERIVED PROTEIN RELATED TO UBIQUITIN  
CONJUGATING ENZYME

TITLE (FRENCH): POLYNUCLEOTIDE CODANT POUR UNE PROTEINE DERIVEE D'UN  
LYMPHOCYTE T HUMAIN ACTIVE LIEE A UNE ENZYME SE  
CONJUGUANT A L'UBIQUITINE

INVENTOR(S): BOWEN, Michael, A., 7812 Polara Place, Rockville, MD  
20855, US;  
WU, Yuli, 3 Susanna Way, Newtown, PA 18940, US;  
YANG, Wen-Ping, 25 Rutgers Lane, Princeton, NJ 08540,  
US;  
FINGER, Joshua, N., Apartment 254, 22 Woodland Parkway,  
San Marcos, CA 92069, US  
BRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000,  
Lawrenceville-Provinceline Road, Princeton, NJ  
08543-4000, US [US, US]

PATENT ASSIGNEE(S): KLEIN, Christopher, A.\$, Bristol-Myers Squibb Company,  
P.O. Box 4000, Lawrenceville-Provinceline Road,  
Princeton, NJ 08543-4000\$, US

AGENT:

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002036741	A2	20020510

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK  
SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

AM AZ BY KG KZ MD RU TJ TM

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US46559 A 20011029

PRIORITY INFO.:

US 2000-60/244,688 20001030

US 2001-60/308,706 20010730

L21 ANSWER 4 OF 8

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

2002006317 PCTFULL ED 20020814

TITLE (ENGLISH):

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS  
OF OVARIAN CANCER

TITLE (FRENCH):

COMPOSITIONS ET PROCEDES UTILISES DANS LA THERAPIE ET  
LE DIAGNOSTIC DU CANCER DES OVAIRES

INVENTOR(S):

MITCHAM, Jennifer, L.;

KING, Gordon, E.;

ALGATE, Paul, A.;

FLING, Steven, P.;

RETTER, Marc, W.;

FANGER, Gary, Richard;

REED, Steven, G.;

VEDVICK, Thomas, S.;

CARTER, Darrick;

HILL, Paul;

ALBONE, Earl

CORIXA CORPORATION;

MITCHAM, Jennifer, L.;

KING, Gordon, E.;

ALGATE, Paul, A.;

FLING, Steven, P.;

RETTER, Marc, W.;

FANGER, Gary, Richard;

REED, Steven, G.;

VEDVICK, Thomas, S.;

CARTER, Darrick;

HILL, Paul;

ALBONE, Earl

Patent

PATENT ASSIGNEE(S):

DOCUMENT TYPE:

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002006317	A2	20020124

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL  
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW  
MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE  
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF  
BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US22635	A 20010717
PRIORITY INFO.:	US 2000-09/617,747	20000717
	US 2000-09/636,801	20000810
	US 2000-09/667,857	20000920
	US 2001-09/827,271	20010404
	US 2001-09/884,441	20010618

=> d kwic 4

L21 ANSWER 4 OF 8 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . Laboratory Manual, Cold Spring Harbor  
Laboratory, 1988. For example, a polypeptide may be immobilized on a  
solid support  
and contacted with patient **sera** to allow binding of  
**antibodies** within the sera to the  
immobilized polypeptide. Unbound sera may then be removed and bound  
antibodies  
detected using, for example, <sup>125</sup>I-labeled. . .

. . .  
RalGDS-like 2 (RGL2)  
21555 (SEQ ID NO:342) human autoantigen P542  
21548 (SEQ ID NO:343) human actin-related protein (ARP2)  
21462 (SEQ ID NO:344) human **huntingtin interacting**  
protein  
21441 (SEQ ID NO:345) human 90K product (tumor associated antigen)  
21439 (SEQ ID NO:346) human guanine nucleotide regulator protein (tim I)  
21438. . .

=> s prosta?

L22 38449 PROSTA?

=> s 122 and 121

L23 6 L22 AND L21

=> d ibib 1-6

L23 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2002094864 PCTFULL ED 20021210 EW 200248  
TITLE (ENGLISH): HUMAN CDNAS AND PROTEINS AND USES THEREOF  
TITLE (FRENCH): ADNC ET PROTEINES HUMAINES, AINSI QUE LEURS  
UTILISATIONS  
INVENTOR(S): BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009  
Paris, FR [FR, FR];  
TANAKA, Hiroaki, 8, avenue de la Providence, F-92160  
Antony, FR [FR, FR]  
PATENT ASSIGNEE(S): GENSET, Intellectual Property Department, 24, rue  
Royale, F-75008 Paris, FR [FR, FR], for all designates  
States except US;  
BEJANIN, Stephane, 35, boulevard Rochechouart, F-75009  
Paris, FR [FR, FR], for US only;  
TANAKA, Hiroaki, 8, avenue de la Providence, F-92160  
Antony, FR [FR, FR], for US only  
AGENT: GENSET\$, Intellectual Property Department, 24, rue  
Royale, F-75008 Paris\$, FR  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
-----		
WO 2002094864	A2	20021128

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
 MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL  
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-IB1715 A 20010806

PRIORITY INFO.:

US 2001-60/293,574 20010525

US 2001-60/298,698 20010615

US 2001-60/302,277 20010629

US 2001-60/305,456 20010713

L23 ANSWER 2 OF 6

ACCESSION NUMBER: PCTFULL COPYRIGHT 2006 Univentio on STN

TITLE (ENGLISH):

2002036741 PCTFULL ED 20020523 EW 200219

POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN  
T-LYMPHOCYTE-DERIVED PROTEIN RELATED TO UBIQUITIN  
CONJUGATING ENZYME

TITLE (FRENCH):

POLYNUCLEOTIDE CODANT POUR UNE PROTEINE DERIVEE D'UN  
LYMPHOCYTE T HUMAIN ACTIVE LIEE A UNE ENZYME SE

CONJUGUANT A L'UBIQUITINE

INVENTOR(S):

BOWEN, Michael, A., 7812 Polara Place, Rockville, MD  
20855, US;WU, Yuli, 3 Susanna Way, Newtown, PA 18940, US;  
YANG, Wen-Ping, 25 Rutgers Lane, Princeton, NJ 08540,  
US;FINGER, Joshua, N., Apartment 254, 22 Woodland Parkway,  
San Marcos, CA 92069, USBRISTOL-MYERS SQUIBB COMPANY, P.O. Box 4000,  
Lawrenceville-Provinceline Road, Princeton, NJ  
08543-4000, US [US, US]

PATENT ASSIGNEE(S):

KLEIN, Christopher, A.\$, Bristol-Myers Squibb Company,  
P.O. Box 4000, Lawrenceville-Provinceline Road,  
Princeton, NJ 08543-4000\$, US

AGENT:

English

LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

-----

WO 2002036741 A2 20020510

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
 MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK  
 SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US46559 A 20011029

PRIORITY INFO.:

US 2000-60/244,688 20001030

US 2001-60/308,706 20010730

L23 ANSWER 3 OF 6

ACCESSION NUMBER: PCTFULL COPYRIGHT 2006 Univentio on STN

TITLE (ENGLISH):

2002006317 PCTFULL ED 20020814  
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS  
OF OVARIAN CANCER

TITLE (FRENCH): COMPOSITIONS ET PROCEDES UTILISES DANS LA THERAPIE ET  
 LE DIAGNOSTIC DU CANCER DES OVAIRES  
 INVENTOR(S): MITCHAM, Jennifer, L.;  
                  KING, Gordon, E.;  
                  ALGATE, Paul, A.;  
                  FLING, Steven, P.;  
                  RETTER, Marc, W.;  
                  FANGER, Gary, Richard;  
                  REED, Steven, G.;  
                  VEDVICK, Thomas, S.;  
                  CARTER, Darrick;  
                  HILL, Paul;  
                  ALBONE, Earl  
 PATENT ASSIGNEE(S): CORIXA CORPORATION;  
                  MITCHAM, Jennifer, L.;  
                  KING, Gordon, E.;  
                  ALGATE, Paul, A.;  
                  FLING, Steven, P.;  
                  RETTER, Marc, W.;  
                  FANGER, Gary, Richard;  
                  REED, Steven, G.;  
                  VEDVICK, Thomas, S.;  
                  CARTER, Darrick;  
                  HILL, Paul;  
                  ALBONE, Earl  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:  

NUMBER	KIND	DATE
WO 2002006317	A2	20020124

 DESIGNATED STATES  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
     CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
     IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
     MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL  
     TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW  
     MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE  
     CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF  
     BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
 WO 2001-US22635       A 20010717  
 US 2000-09/617,747     20000717  
 US 2000-09/636,801     20000810  
 US 2000-09/667,857     20000920  
 US 2001-09/827,271     20010404  
 US 2001-09/884,441     20010618  
 APPLICATION INFO.:  
 PRIORITY INFO.:  
 DESIGNATED STATES  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
     CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
     IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
     MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL  
     TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW  
     MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE  
     CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF  
     BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG  
 WO 2001-US22635       A 20010717  
 US 2000-09/617,747     20000717  
 US 2000-09/636,801     20000810  
 US 2000-09/667,857     20000920  
 US 2001-09/827,271     20010404  
 US 2001-09/884,441     20010618  
 L23 ANSWER 4 OF 6  
 ACCESSION NUMBER: PCTFULL COPYRIGHT 2006 Univentio on STN  
 2000076531 PCTFULL ED 20020515  
 TITLE (ENGLISH): 47 HUMAN SECRETED PROTEINS  
 TITLE (FRENCH): 47 PROTEINES HUMAINES SECRETEES  
 INVENTOR(S): ROSEN, Craig, A.;  
                 RUBEN, Steven, M.;  
                 KOMATSOULIS, George, A.RP : HOOVER, Kenley, K.  
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;  
                  ROSEN, Craig, A.;  
                  RUBEN, Steven, M.;  
                  KOMATSOULIS, George, A.  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:  

NUMBER	KIND	DATE
WO 2000076531	A1	20001221

 DESIGNATED STATES

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE  
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE  
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX  
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA  
UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG  
ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI  
FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN  
GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US15137 A 20000601  
PRIORITY INFO.: US 1999-60/138,625 19990611

L23 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 2000018916 PCTFULL ED 20020515  
TITLE (ENGLISH): HUMAN GENES AND GENE EXPRESSION PRODUCTS  
TITLE (FRENCH): GENES HUMAINS ET PRODUITS D'EXPRESSION GENIQUE  
INVENTOR(S): WILLIAMS, Lewis, T.;  
ESCOBEDO, Jaime;  
INNIS, Michael, A.;  
GARCIA, Pablo, Dominguez;  
SUDDUTH-KLINGER, Julie;  
REINHARD, Christoph;  
GIESE, Klaus;  
RANDAZZO, Filippo;  
KENNEDY, Giulia, C.;  
POT, David;  
KASSAM, Altaf;  
LAMSON, George;  
DRMANAC, Radoje;  
CRKVENJAKOV, Radomir;  
DICKSON, Mark;  
DRMANAC, Snezana;  
LABAT, Ivan;  
LESHKOWITZ, Dena;  
KITA, David;  
GARCIA, Veronica;  
JONES, Lee, William;  
STACHE-CRAIN, Birgit  
CHIRON CORPORATION;  
HYSEQ INC.

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000018916	A2	20000406

DESIGNATED STATES

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE  
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE  
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO  
NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ  
VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY  
KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE  
IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE  
SN TD TG

APPLICATION INFO.: WO 1999-US22226 A 19990923  
PRIORITY INFO.: US 1998-60/102,161 19980928  
US 1998-60/102,180 19980928  
US 1998-60/102,380 19980929  
US 1998-60/103,815 19981008  
US 1998-60/105,877 19981027

L23 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN  
ACCESSION NUMBER: 1999038972 PCTFULL ED 20020515  
TITLE (ENGLISH): HUMAN GENES AND GENE EXPRESSION PRODUCTS II

TITLE (FRENCH): GENES HUMAINS ET PRODUITS II D'EXPRESSION GENIQUE  
INVENTOR(S): WILLIAMS, Lewis, T.;  
ESCOBEDO, Jaime;  
INNIS, Michael, A.;  
GARCIA, Pablo, Dominguez;  
SUDDUTH-KLINGER, Julie;  
REINHARD, Christoph;  
GIESE, Klaus;  
RANDAZZO, Filippo;  
KENNEDY, Giulia, C.;  
POT, David;  
KASSAM, Altaf;  
LAMSON, George;  
DRMANAC, Radoje;  
CRKVENJAKOV, Radomir;  
DICKSON, Mark;  
DRMANAC, Snezana;  
LABAT, Ivan;  
LESHKOWITZ, Dena;  
KITA, David;  
GARCIA, Veronica;  
JONES, Lee, William;  
STACHE-CRAIN, Birgit  
CHIRON CORPORATION;  
HYSEQ INC.;  
WILLIAMS, Lewis, T.;  
ESCOBEDO, Jaime;  
INNIS, Michael, A.;  
GARCIA, Pablo, Dominguez;  
SUDDUTH-KLINGER, Julie;  
REINHARD, Christoph;  
GIESE, Klaus;  
RANDAZZO, Filippo;  
KENNEDY, Giulia, C.;  
POT, David;  
KASSAM, Altaf;  
LAMSON, George;  
DRMANAC, Radoje;  
CRKVENJAKOV, Radomir;  
DICKSON, Mark;  
DRMANAC, Snezana;  
LABAT, Ivan;  
LESHKOWITZ, Dena;  
KITA, David;  
GARCIA, Veronica;  
JONES, Lee, William;  
STACHE-CRAIN, Birgit  
English  
Patent

LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9938972	A2	19990805

DESIGNATED STATES  
W:  
AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT  
RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU  
ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ  
TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT  
SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
WO 1999-US1619 A 19990128  
US 1998-60/072,910 19980128  
US 1998-60/075,954 19980224

US 1998-60/080,114 19980331  
US 1998-60/080,515 19980403  
US 1998-60/080,666 19980403

=> d kwic 3

L23 ANSWER 3 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . Laboratory Manual, Cold Spring Harbor  
Laboratory, 1988. For example, a polypeptide may be immobilized on  
solid support  
and contacted with patient sera to allow binding of  
**antibodies** within the sera to the  
immobilized polypeptide. Unbound sera may then be removed and bound  
antibodies  
detected using, for example,  $^{125}\text{I}$ -labeled. . . .

RalGDS-like 2 (RGL2)  
21555 (SEQ ID NO:342) human autoantigen P542  
21548 (SEQ ID NO:343) human actin-related protein (ARP2)  
21462 (SEQ ID NO:344) human **huntingtin interacting**  
protein  
21441 (SEQ ID NO:345) human 90K product (tumor associated antigen)  
21439 (SEQ ID NO:346) human guanine nucleotide regulator protein (tim I)  
21438. . .

For generation of polyclonal anti-sera, 400 micrograms of each prostate antigen was combined with 100 micrograms' of muramyl dipeptide (MDP). Equal volume of Incomplete Freund's Adjuvant (IFA) was added and then mixed. Every four weeks. . .

=> d kwic 6

L23 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD data too large for display

=> d kwic 5

L23 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . can be assayed in body fluids that are convenient, such as blood, plasma, serum, and other body fluids such as urine, **prostatic** fluid and semen. Membrane-bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or. . .

The invention also contemplates naturally occurring antibodies specific for a polypeptide of the invention. For example, **serum antibodies** to a polypeptide of the invention in a human population can be purified by methods well known in the art,. . .

. . sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e.g., brain, thymus, testis, heart, **prostate**, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA,. . .

3 5 Detection of **prostate** cancer. The polynucleotides and their corresponding genes and gene

3 8 products exhibiting the appropriate differential expression pattern can be used to detect **prostate** cancer in a subject. Over 95% of primary **prostate** cancers are adenocarcinomas. Signs and symptoms may include: frequent urination, especially at night, inability to urinate, trouble starting or holding back urination,. . .

Many of the signs and symptoms of **prostate** cancer can be caused by a variety of other non-cancerous conditions. For example, one common cause of many of these signs and symptoms is a condition called benign **prostatic** hypertrophy, or BPH. In BPH, the **prostate** gets bigger and may block the flow of urine or interfere with sexual function. The methods and compositions of the invention can be used to distinguish between **prostate** cancer and such non-cancerous conditions.

. . invention can be used in conjunction with conventional methods of diagnosis, e.g., digital rectal exam and/or detection of the level of **prostate** specific antigen (PSA), a substance produced and secreted by the **prostate**.

. . gland double-headed protease inhibitors, which contain two Kazal-type domains, the first one inhibits trypsin and the second one elastase. a mouse **prostatic** secretary glycoprotein, induced by androgens, and which exhibits anti-trypsin activity-, avian ovomucoids; chicken ovoinhibitor; and the leech trypsin inhibitor Bdellin B The. .

. . cDNA library)

20 Liver Metastasis from Colon Tumor of UC#3 Patient 30956

(MICRODISSECTED PCR (OligodT) cDNA library)  
21 GRRpz Cells derived from normal **prostate** epithelium 164801  
22 WOca Cells derived from Gleason Grade 4 **prostate** 162088  
cancer epithelium  
23 Normal Lung Epithelium of Patient # 1 006 306198  
(MICRODISSECTED PCR (OligodT) cDNA library)  
Primary tumor, Large Cell Carcinoma of. . .

Donna M. Peehl, Department of Medicine, Stanford University School of Medicine. GRRpz was derived from normal **prostate** epithelium. The WOca cell line is a Gleason Grade 4 cell line.

genome IE-35  
490 JABO16492.1 Homo sapiens hJTB gene, complete cds e-I 18  
491 X98176 H.sapiens mRNA for MACH-beta- I protein IE-36  
Homo sapiens **huntingtin interacting protein HYPK**  
mRNA,  
492 AF049613 partial cds 7E-22  
493 AF039690.1, HomosapiensantigenNY-CO-8(NY-CO-8)mRNA,partialeds IE-37  
INM-001003I Homo sapiens ribosomal protein, large, PI ribosomal  
494 phosphoprotein PI mRNA, complete cds.. . .  
of 3] 1.9  
5 Homo sapiens retinal pigment epithelium-specific protein  
588 AF039857 (RPE65) gene, exon 3 0.023  
589 X05034 Rat C2A gene for **prostatic** binding protein (PBP)  
0.2  
Rattus norvegicus clone ubc4a ubiquitin conjugating enzyme  
590 U13177 (E217kB) rnRNA, complete cds. 0.071  
591 AF081530 Homo sapiens neuralized. . .  
beta-globin mRNA, 5'UTR. 0.03  
Haemophilus influenzae Rd section 107 of 163 of the complete  
684 U32792 genorne 2.1  
685 X74969 R.norvegicus gene for **prostatic** acid phosphatase  
0.02  
Phanerochaete chrysosporium manganese peroxidase isozyme 3  
686 U70998 (mnp3) gene, complete cds 0.73  
Homo sapiens nucleosome assembly protein I-like 4. . .  
=> d kwic 4  
  
L23 ANSWER 4 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN  
  
DETD . . . cells-treated with estradiol; Smooth muscle, IILb induced;  
Synovial hypoxia-  
RSF subtracted; Human Whole Brain #2 - Oligo dT > 1.5Kb; LNCAP  
**prostate** cell  
line; HL-60, PMA 4H, re-excision; Synovial hypoxia; Jurkat T-cell GI  
phase; Brain  
Frontal Cortex, re-excision; Human Umbilical Vein, Reexcision; HUMAN  
JURKAT  
MEMBRANE. . .  
  
(10 nM 132) fraction 1; Activated T-cells; Human T-cell  
lymphoma, re-excision; Soares retina N2b4HR; STRONIAL -OSTEOCLASTOMA;  
Soares pregnant uterus NbHPU; Synovial hypoxia-RSF subtracted;  
**Prostate** BPH;  
NCI\_CGAP\_Co3; NCI\_CGAP-GCB 1; Monocyte activated, re-excision; Human  
Pancreas Tumor, Reexcision; Olfactory epithelium,nasalcavity; Human  
Placenta (re-  
excision); Human Activated T-Cells, re-excision; Ulcerative Colitis;. . .

. Synovial IL-  
I/TNF stimulated; Human endometrial stromal cells-treated with  
progesterone;  
Human Osteoclastoma, re-excision; Human Adult Small Intestine; Human  
Neutrophil; Human Chronic Synovitis; Human **Prostate**; Human  
Thymus;  
NCI-CGAP-Br3; NCI\_CGAP-co8; NCI\_CGAP-co9; NCI\_CGAP-Kid3;  
NCI-CGAP-Larl; NCI\_CGAP-Prl 1; 12 Week Old Early Stage Human, 11; HUMAN  
JURKAT MEMBRANE BOUND POLYSOMES; T-Cell PHA. . .

gil3341980 (all information available through the recited accession  
number is  
incorporated herein by reference) which is described therein as  
**huntingtin-interacting**  
protein HYPA/FBP1 I ['Homo sapiens]. A partial alignment demonstrating  
the  
observed homology is shown immediately below.

>gil3341980 (AF049523) **huntingtin-interacting**  
protein HYPA/FBP11 [Homo  
sapiens]  
>SP10754001075400 **HUNTINGTIN-INTERACTING PROTEIN**  
HYPA/FBP11  
(FRAGMENT). >gil3341982 (AF049524) **huntingtin-**  
**interacting**  
protein  
HYPA/FBP11 [Homo sapiens] fSUB 17-1831 >giII255025 FBP 11 [Mus  
musculus] fSUB 121-1871  
Length = 423  
Plus Strand HSPs.  
. . .  
Synovial Fibroblasts (control); Soares breast 3NbHBst; NCI CGAP CA  
Jurkat Cells, cyclohexamide treated, subtraction; NCI\_CGAP-GC4;  
NCI-CGAP-GCB I; NCI-CGAP-Brn23; Soares-testis\_NHT;  
Soares-total-fetus-Nb2HF8-9w; Human Lung; Soares-pregnant-Uterus-NbHPU;  
Human **Prostate** Cancer, Stage C fraction; NTERA2 + retinoic  
acid, 14 days; Salivary  
Gland, Lib 2; Stratagene endothelial cell 937223; Human Umbilical Vein,  
Reexcision; . . . (#937210); Human Liver,  
normal; Soares-pregnant-uterus-NbHPU; Pancreatic Islet;  
Soares-placenta-8to9weeks-2NbHP8to9W; Primary Dendritic cells,frac 2;  
NCI-CGAP-GCB 1; T cell helper 11; Soares fetal liver spleen I NFLS;  
**Prostate/LNCAP**, subtraction 1; Human Umbilical Vein  
Endothelial Cells, fract. B;  
Whole brain; Human Tongue, frac 1; Clontech human aorta polyA+ mRNA  
(#6572);  
Human. . . Human Amygdala, re-excision; Human Osteoclastoma, re-  
excision; Stratagene ovarian cancer (#937219); Human endometrial stromal  
cells;  
Human Manic Depression Tissue; Spleen metastatic melanoma; Human  
**Prostate**;  
KMH2; Human Thymus; Apoptotic T-cell; HUMAN JURKAT MEMBRANE  
BOUND POLYSOMES; Human Heart; Human Ovary; Rejected Kidney, lib 4;  
CHME Cell Line, treated 5 hrs; . . .  
. . .  
cell line, remake; HSC172 cells; Supt  
Cells, cyclohexamide treated; Activated T-Cells, 12 hrs, re-excision;  
Messangial cell,  
frac 2; Human Epididymus; Stratagene placenta (#937225); LNCAP  
**prostate** cell line;  
Human Osteosarcoma; Human Colon, re-excision; H. Kidney Medulla,  
re-excision;  
Human Bone Marrow, re-excision; Human Fetal Kidney; Human Umbilical Vein  
Endothelial Cells, . . .

Heart, re-excision; Human adult small intestine, re-excision; Human Lung Cancer, re-excision; Apoptotic T-cell, re-excision;  
Soares-pineal-gland\_N3HPG; HEL cell line; Stomach cancer (human), re-excision;  
Human Colon Cancer, re-excision; STROMAL -OSTEOCLASTOMA; Human **Prostate** Cancer, Stage C fraction; pBMC stimulated w/ poly I/C; Alzheimers, spongy change; Human Umbilical Vein, Endo. remake; Synovial hypoxia-RSF subtracted;  
Human Stomach, re-excision; . . .  
fetal spleen (#937205); Human Adult Testes, Large Inserts, Reexcision; Hemangiopericytoma; Pancreas Islet Cell Tumor; NCI\_CGAP-GCB I;  
Soares-parathyroid-tumor-NbHPA; normalized infant brain cDNA; PC3 **Prostate** cell line; Human Synovial Sarcoma; Endothelial-induced; Keratinocyte; Soares-fetal-heart-NbHH19W; Larynx Normal; H. Frontal Cortex, Epileptic; Soares I  
-pineal gland N3HPG; H Umbilical Vein Endothelial Cells,. . .  
Activated T-Cells, re-excision; NCI\_CGAP-Kid3;  
NCI-CGAP-Brn25; Human Testes Tumor, re-excision; CHME Cell Line, treated 5 hrs; Hepatocellular Tumor, re-excision; Pancreas Islet Cell Tumor; PC3 **Prostate** cell line; Colon Tumor; Smooth muscle, serum treated; Human Placenta; NCI\_CGAP-Br2; NCI-CGAP-GC4; NCI\_CGAP-Kid3; NCI\_CGAP-Kid6; NCI\_CGAP\_Pri2; Colon Tumor 11; Human Synovial Sarcoma; Human fetal. .  
Human skeletal muscle cDNA library, cat. #936215.;  
Soares-testis-NHT; Stratagene lung carcinoma 937218; Subtracted human retinal pigment epithelium (RPE); Spleen/normal; Colon Normal; Human **Prostate**, subtracted; Human epithelioid sarcoma; stomach cancer (human); HUMAN STOMACH; Activated T-cells; Human Thyroid; Human Lung; Human Epididymus; Human Hypothalamus, schizophrenia, re-excision; Human Osteosarcoma; Synovial Fibroblasts (11 I/TNF), subt; Human Manic Depression Tissue; Spleen metastatic melanoma; Human Adult Small Intestine; Human Neutrophil; Human **Prostate**; 12 Week Old Early Stage Human, 11; Human Umbilical Vein Endothelial Cells, uninduced; Human Fetal Dura Mater; Liver, Hepatoma; Ulcerative Colitis; Human Fetal. . .  
A; Monocyte activated; Human Bone Marrow, treated; Hodgkin's Lymphoma 11; Morton Fetal Cochlea; H. Striatum Depression, subt; HUMAN STOMACH; Human Epididymus; Human **Prostate** Cancer, Stage C fraction; Human Osteosarcoma, re-excision; Human **Prostate**; T-Cell PHA 16 hrs; Human colorectal cancer; Soares-NhHMPu\_S I; Temporal cortex-Alzheimer, subtracted; Monocyte activated, re-excision; Stratagene fetal spleen (#937205); T-Cell PHA 24. . .  
hypothalamus, frac A; Human Whole 6 Week Old Embryo (11), subt; Salivary Gland,

Lib 3; LNCAP + 3OnM R1881; Human **Prostate**, subtracted; Saos2 Cells, Vitamin D3  
Treated; Saos2, Dexamethosome Treated; Human OB HOS treated (I nM E2) fraction 1; Human Colon, subtraction; Human. . .  
. . .  
i um (#93723 1); Stratagene ovary (#937217); HL-60, PMA 4H, re-excision; Jurkat T-cell G I phase; Human Thymus; NCI-CGAP-Co3; NCI-CGAP-SSI; PC3 **Prostate** cell line; CHME Cell Line,untreated; Soares breast  
3NbHBst; Human Fetal Kidney, Reexcision; Human Synovial Sarcoma; Soares-fetal-heart-NbHH19W; Soares-NhHMPu\_S I; Bone Marrow Cell Line (RS4,1 1); Stratagene HeLa cell s3 937216; Keratinocyte; Scares placenta Nb2HP;  
Soares\_NhHMPu\_S I; Normal **Prostate**; Whole 6 Week Old Embryo; Human colon carcinoma (HCQ cell line, remake; Human Cerebellum, subtracted; Human Placenta;  
H. Epididymus, caput & corpus;. . . retina N2b4HR;  
Soares\_NhHMPu\_S I; Apoptotic T-cell, re-excision; Stomach cancer (human), re-excision; NTERA2 + retinoic acid, 14 days; Jurkat T-Cell, S phase; wilm's tumor;  
**Prostate** BPH; H. Lymph node breast Cancer; TF- I Cell Line GM-CSF Treated;  
Breast Cancer Cell line, anglogenic; Human Fetal Kidney; HUMAN. . .  
. . .  
Whole Embryo; Soares placenta  
Nb2HP; Salivary gland, re-excision; Human White Fat; Human Colon Cancer,re-excision; Soares\_multiple\_sclerosls-2NbHMSP; Salivary Gland, Lib 2; Human Colon, re-excision; **Prostate** BPH; Human Adult Small Intestine; Mo7e Cell Line  
GM-CSF treated (I ng/ml); Temporal cortex-Alzhelzmer, subtracted; Soares-multiple-scierosis-2NbHMSP; Human Hypothaimus,Schizophrenia; NCI-CGAP-Lu5; NCI\_CGAP-Kid3; Olfactory epithelium,nasalcavity; Human Adipose;. . .  
. . .  
extent in Macrophage (GM-CSF treated);  
Soares-senescent-fibroblasts-NbHSF; Human Adult Spleen;  
Adipocytes,re-excision;  
Human Pineal Gland; pBMC stimulated w/ poly I/C; Glioblastoma; Human Pituitary,  
subt IX; **Prostate** BPH; T-Cell PHA 24 hrs; Human Chondrosarcorna; Soares adult brain N2b5HB55Y; Human Adrenal Gland Tumor;  
Soares\_NSF\_F8\_9W\_0T\_PA\_P\_S1; Soares-fetal-liver-spleen-INFLS\_S1; Smooth muscle, serum induced,re-exc; Human Gall. . .  
. . .  
Adult Small Intestine; Human 8 Week Whole Embryo and to a lesser extent in Human Pineal Gland; Kidney medulla; Larynx carcinoma IV;  
**Prostate**; Soares retina N2b4HR; Breast Cancer cell line, MDA 36; Human  
Osteosarcoma; Scares melanocyte 2NbHM; Endothelial cells-control; Human brain frontal cortex; NCI-CGAP-Lu5; NCI\_CGAP-GCB. . .  
. . .  
Kidney Medulla, re-excision; human ovarian cancer; Stromal cell TF274; Human Adipose; Human Rhabdomyosarcoma; Soares-NFL-T\_GBC\_S I; PO **Prostate** cell line; CHME Cell Line,untreated; Soares I -pregnant-uterus\_NbHPU; Stratagene

fibroblast (#937212); Colon Tumor 11; Normal colon;  
Soares-multiple-scierosis-2NbHMSP; Human Fetal Heart; NCI\_CGAP-Prl;  
Hodgkin's Lymphorna 11; Human. . . Express; Human  
Macrophage; Human Rejected Kidney, 704 re-excision;  
Soares-total-fetus-Nb2HF8-9w; Colon Normal; Larynx Normal; Human Pre-  
Differentiated Adipocytes; Activated T-Cells, 8 hrs, subtracted; Human  
**Prostate**,  
subtracted; Saos2, Dexamethosome Treated; **prostate**-edited;  
Human Aortic  
Endotheliurn; SKIN; Human Umbilical Vein Endothelial Cells, fract. A;  
Human fetal  
heart, Lambda ZAP Express; NCI\_CGAP\_Kid3; Adipocytes, re-excision; Smooth  
Muscle Serum Treated,. . . zero hr post-incision (control);  
Pancreas Tumor PCA4 Tu; Human Synovium; Stratagene endothelial cell  
937223;  
Synovial IL-I/TNF stimulated; Smooth muscle, ILIb induced; LNCAP  
**prostate** cell  
line; Human Adipose Tissue, re-excision; Synovial hypoxia; Healing groin  
wound,  
6.5 hours post incision; **Prostate** BPH; Human Adult Small  
Intestine;  
Soares-multiple-scierosis-2NbHMSP; TF- I Cell Line GM-CSF Treated; Human  
Brain, Striatum; Stratagene fetal spleen (#937205); 12 Week Old. . .  
. . .  
human ovarian cancer; Human  
Uterine Cancer; Human Placenta (re-excision); Human Chondrosarcoma;  
NTERA2,  
control; Human Gall Bladder; Clontech human aorta polyA+ rRNA (#6572);  
PC3  
**Prostate** cell line; Human Testes Tumor; Colon Tumor 11;  
Dendritic cells, pooled;  
Human Fetal Lung 111; Human Amygdala; NCI\_CGAP-Co3; Osteoblasts; Healing  
groin wound, 6.5 hours post incision; H. Meningima, MI; Human  
Neutrophil; Human  
**Prostate**; Soares\_NhHMPu\_S 1; KNIH2; Soares-total-fetus-Nb2HF8-  
9w; Human  
Fetal Dura Mater; T-Cell PHA 24 hrs; Human Ovary; Human fetal heart,  
Lambda  
ZAP Express; Rejected Kidney,. . . Human Synovium; Hepatocellular  
Tumor, re-excision; Stratagene placenta (#937225); Synovial. hypoxia-RSF  
subtracted;  
Glioblastoma; Healing groin wound, 7.5 hours post incision; Salivary  
Gland, Lib 2;  
LNCAP **prostate** cell line; Human endometrial stromal cells;  
Soares-pregnant-uterus-NbHPU; **Prostate** BPH; Human Infant  
Brain; Hippocampus,  
Alzheimer Subtracted; H. Kidney Medulla, re-excision; Gessler Wilms  
tumor;  
Soares-fetal-heart-NbHH19W; L428; Human Pancreas Tumor; Human  
Hypothalmus, Schizophrenia; Pancreatic Islet; . . .  
. . .  
Human Microvascular  
Endothelial Cells, fract. A; Smooth muscle, control; Soares fetal liver  
spleen I NFLS;  
Soares ovary tumor NbHOT; Raji Cells, cyclohexamide treated;  
Glioblastorna;  
**Prostate** BPH; Human Bone Marrow, re-excision; human ovarian  
cancer; Stromal cell  
TF274; Adipocytes; Human Testes Tumor; Keratinocyte; T cell helper 11;  
Cem. . . Nigra;  
Human Adult Pulmonary, re-excision; HUMAN B CELL LYMPHOMA;  
JNCI CGAP GCB I; Human Cerebellum; Whole 6 Week Old Embryo; Human Adult  
Liver, subtracted; **prostate**-edited; LI Cell line; Human Adult  
Spleen; Human Colon;

Human White Adipose; Human Thyroid; Human Lung; Stratagene ovary (#937217);  
H. Whole Brain #2, re-excision; Human Umbilical Vein, Endo. remake;  
Healing  
groin wound, 7.5 hours post incision; LNCAP **prostate** cell  
line; HL-60, PMA 4H, re-  
excision; Spleen metastatic melanoma; Stratagene ovarian cancer (#937219);  
H. Kidney  
Medulla, re-excision; CD34 depleted Buffy Coat. . . Fetal Heart;  
Human  
Amygdala; Soares-fetal-liver-spleen\_INFLS\_S1; Soares-fetal-lung-NbHL19W;  
Human Endometrial Tumor; Stratagene fibroblast (#937212); Stratagene  
endothelial  
cell 937223; Human Fetal Brain; HT29M6; Human Myometrium Leiomyoma;  
Human **Prostate** Cancer, Stage C; Human Infant Adrenal Gland;  
Human Adult Liver;  
Activated T-Cells, 8 hrs, differentially expressed; Jurkat Cells,  
cyclohexamide  
treated, subtraction; HeLa. . . subtracted;  
Soares-testis-NHT; Soares\_NFL-T-GBC-SI; Stratagene hNT neuron (#937233);  
Supt cells, cyclohexamide treated, subtracted; Human Gastrocnemius;  
Normal  
trachea; Bone marrow stroma, treated; Testis, normal; Duodenum; Human  
**Prostate**  
Cancer, Stage 132; HPAS (human pancreas, subtracted); Raji cells,  
cyclohexamide  
treated, subtracted; Human B Cell 8866; Human Thymus Tumor, subtracted;  
Testes;  
Thymus; Human Tonsil, Lib 3; Hypothalamus; Human **Prostate**  
Cancer, Stage B2  
fraction; H. Normalized Fetal Liver, 11; Human epithelioid sarcoma;  
HL-60, RA 4h,  
Subtracted; Dermatofibrosarcoma Protuberance; LNCAP untreated; Frontal  
Lobe,  
Dementia;. . . Cell, untreated; Human Thymus  
Stromal Cells; Soares-pregnant-uterus-NbHPU; Fetal Liver, subtraction  
11; Ovarian  
Tumor 10 95; Pancreas Islet Cell Tumor; NCI-CGAP-Br2; Fetal Heart; PC3  
**Prostate** cell line; Human T-Cell Lymphorna; Human Eosinophils;  
breast lymph node  
CDNA library; Human Placenta; Human adult (K.Okubo); Human fetal heart,  
Lambda ZAP. . .

In another specific embodiment of the present invention, the kit is a diagnostic  
kit for use in screening **serum** containing **antibodies**  
specific against proliferative  
and/or cancerous polynucleotides and polypeptides. Such a kit may  
include a control  
antibody that does not react with the. . .

. . .  
an inflammatory response. These molecules  
can be used to treat, prevent, and/or diagnose inflammatory conditions,  
both chronic  
and acute conditions, including chronic **prostatitis**,  
**granulomatous prostatitis** and  
malacoplakia, inflammation associated with infection (e.g., septic  
shock, sepsis, or  
systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion  
injury,  
endotoxin lethality, arthritis, complement-mediated hyperacute. . .

. . .  
which may be treated, prevented, and/or diagnosed with polynucleotides,  
polypeptides, antagonists and/or agonists include, but are not limited

to solid tumors,  
including **prostate**, lung, breast, ovarian, stomach, pancreas,  
larynx, esophagus, testes,  
liver, parotid, biliary tract, colon, rectum, cervix, uterus,  
endometrium, kidney,  
bladder, thyroid cancer; primary. . .

. . .  
cancer,  
melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer,  
testicular  
cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma,  
endothelioma,  
osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma,  
breast  
cancer, **prostate** cancer, Kaposi's sarcoma and ovarian cancer);  
autoimmune diseases,  
disorders, and/or conditions (such as, multiple sclerosis, Sjogren's  
syndrome,  
Hashimoto's thyroiditis, biliary cirrhosis, Behcet's. . .

. . .  
myxosarcoma, liposarcoma,  
chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,  
endotheliosarcoma,  
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma,  
Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma,  
pancreatic  
cancer, breast cancer, ovarian cancer, **prostate** cancer,  
squamous cell carcinoma, basal  
cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland  
carcinoma,  
papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,  
medullary  
carcinoma, bronchogenic carcinoma,. . .

. . .  
example of such methods, cells  
expressing a polypeptide of the present invention is administered to an  
animal to  
induce the production of **sera** containing polyclonal  
**antibodies**. In a preferred  
method, a preparation of the secreted protein is prepared and purified  
to render it  
substantially free of natural contaminants.. . .

. . .  
Chapter 2.) As one example of such methods,  
cells expressing XXX are administered to an animal to induce the  
production of **sera**  
1 5 containing polyclonal **antibodies**. In a preferred method, a  
preparation of XXX  
protein is prepared and purified to render it substantially free of  
natural contaminants.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

24.34

SESSION

51.48

STN INTERNATIONAL LOGOFF AT 13:57:04 ON 30 MAY 2006